The following are examples utilizing advanced imaging technologies in biomedical product development.

 
Angiogenic Gene Therapy

>	Myocardial perfusion and ventricular function followed throughout therapy using MRI blood pool contrast agents.

Vascular Stent-Graft

>	CT angiography evaluates success of graft placement, while MR spectroscopy of calf muscle evaluates metabolism as a reflection of improved perfusion.

Neuroprotective Pharmaceutical for Stroke Patients

>	MR imaging, including perfusion and diffusion imaging, fused with PET studies to provide comprehensive, anatomic and pathophysiologic quantitative information.

Assay for Metastatic Epithelial Tumors

>	Helical CT with 3D tumor volumetrics assesses changes in individual tumor size, perfusion, and overall tumor bulk.

Multiple Sclerosis Therapy

>	Placque size measured using contrast-enhanced MRI demonstrates a decrease in plaque size and activity with drug therapy.

Breast Cancer Hormone Therapy

>	Chemo prevention therapy monitoring uses magnetic resonance spectroscopy to evaluate for premalignant changes.

Concurrent CT/PET to localize anatomy of drug action

>	Biologic activity and biodistribution of new compounds by tagging with an appropriate nuclear metabolic radiotracer and then imaging with new scanners that combine CT for fine anatomic detail and PET for high sensitivity of drug localization/metabolism.

Uterine Fibroid Therapy

>	Color Doppler ultrasound is used to follow the effects of oral treatment, measuring size and blood flow changes with each fibroid tumor.

Hypercholesterolemia and Systemic Atherosclerotic Placque Therapies

>	MRI and MRS of carotid arteries establishes plaque content and extent during clinical trials to establish efficacy.